Novel Oral Anticoagulants & The Risk of Bleeding in Elderly Patients
The bleeding risk of novel oral anticoagulants relative to warfarin in patients ≥ 75 years of age is unknown. A systematic review and meta-analysis have indicated differing patterns of risk with dabigatran being associated with the highest risk for GI bleeding. There is currently insufficient data for the bleeding risk of apixaban, rivaroxaban, and edoxaban in this population.
For more, click here